BofA analyst Jason Gerberry lowered the firm’s price target on Biohaven (BHVN) to $14 from $15 and keeps a Neutral rating on the shares. Biohaven’s Q4 release was “uneventful and largely a reiteration of R&D pipeline program timelines,” according to the analyst, whose price target revision is driven by higher near-term cash burn and incorporation of recent financing in the firm’s model.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BHVN:
- Maintaining Hold on Biohaven: Encouraging Early Signals but Awaiting Placebo-Controlled Data and Funding Clarity
- Biohaven reports Q4 adjusted EPS (90c), consensus (96c)
- Biohaven initiated with a Buy at Goldman Sachs
- Midday Fly By: Netflix reports Q4 beat, Smithfield to acquire Nathan’s
- Biohaven upgraded to Outperform from Sector Perform at RBC Capital